XHKG
2197
Market cap78mUSD
Jul 18, Last price
0.48HKD
1D
-1.04%
1Q
142.35%
IPO
-94.84%
Name
Clover Biopharmaceuticals Ltd
Chart & Performance
Profile
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
Income | ||||||
Revenues | 38,419 -2.13% | 39,255 | ||||
Cost of revenue | 989,626 | 772,139 | 2,054,037 | |||
Unusual Expense (Income) | ||||||
NOPBT | (951,207) | (732,884) | (2,054,037) | |||
NOPBT Margin | ||||||
Operating Taxes | (229) | |||||
Tax Rate | ||||||
NOPAT | (951,207) | (732,884) | (2,053,808) | |||
Net income | (903,428) 552.11% | (138,539) -94.35% | (2,451,674) -59.26% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 84 | 453,155 | ||||
BB yield | -0.01% | -15.88% | ||||
Debt | ||||||
Debt current | 86,149 | 326,598 | 317,630 | |||
Long-term debt | 19,173 | 34,241 | 97,046 | |||
Deferred revenue | 2,496,900 | |||||
Other long-term liabilities | 537,884 | 549,411 | 2,496,900 | |||
Net debt | (322,205) | (392,133) | (1,225,905) | |||
Cash flow | ||||||
Cash from operating activities | (727,878) | (1,690,809) | ||||
CAPEX | (6,952) | (105,560) | ||||
Cash from investing activities | (6,161) | (37,506) | ||||
Cash from financing activities | (142,408) | 483,143 | ||||
FCF | 205,154 | (351,304) | (2,236,723) | |||
Balance | ||||||
Cash | 427,527 | 752,972 | 1,640,581 | |||
Long term investments | ||||||
Excess cash | 425,606 | 751,009 | 1,640,581 | |||
Stockholders' equity | (1,636,272) | (9,639,430) | (9,230,511) | |||
Invested Capital | 627,502 | 9,790,459 | 13,904,258 | |||
ROIC | ||||||
ROCE | 94.29% | |||||
EV | ||||||
Common stock shares outstanding | 1,253,673 | 1,243,504 | 1,102,104 | |||
Price | 0.24 -61.13% | 0.62 -76.06% | 2.59 -80.81% | |||
Market cap | 302,135 -60.81% | 770,973 -72.99% | 2,854,448 -54.25% | |||
EV | (20,070) | 378,840 | 1,628,543 | |||
EBITDA | (951,207) | (658,142) | (1,993,943) | |||
EV/EBITDA | 0.02 | |||||
Interest | 18,723 | 5,930 | ||||
Interest/NOPBT |